Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population

Inclusion Criteria: * The subject did not adequately respond (i.e., did not achieve or maintain \> 5%weight loss) to an appropriate non-pharmacologic weight-reducing regimen (i.e., diet and exercise) within 3 months prior to Screening. * The subject was male or female and between 18 and 65 years of age. * The subject has nutritional obesity and BMI \>= 27 kg/m2 associated with dyslipidemia or has BMI \>= 30 kg/m2. * Dyslipidemia was defined as having at least one of the following three conditions: * Low-density lipoprotein (LDL)-cholesterol level of \> 3.4 mmol/L (\> 130 mg/dL) * total cholesterol level of \> 5.2 mmol/L (\> 200 mg/dL) * triglyceride level of \> 1.7 mmol/L (\> 150 mg/dL). 254 * If the subject was female * she must either not of childbearing potential: defined as postmenopausal for at least 2 years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), * or was of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)on contraceptives (oral or parenteral) for the 3-month period prior to Week 0, a vasectomized partner, total abstinence from sexual intercourse * If the subject was female, the results of a urine pregnancy test performed at Screening and Week 0 were negative. * If the subject was female, the subject was not breast-feeding. * The subject was judged to be in general good health based upon the results of medical history, complete physical examination and clinical laboratory tests. * The subject was not taking any over-the-counter or prescription drugs, or herbal products for weight loss during the 4 week period prior to Screening. * The subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to undertaking any study-specific procedures Exclusion Criteria: * History or evidence according to the 1997 American Diabetic Association (ADA)26criteria of type 1 or type 2 diabetes mellitus, i.e., fasting plasma glucose level \>= 7.0 mmol/L. * Inadequately controlled hypertension having systolic blood pressure \>= 145 mmHg or diastolic blood pressure \>= 90 mmHg (average of three measurements) or any hypertensive subjects taking \> 3 medications to control blood pressure. * History of Gilles de la Tourette's Syndrome. * Use within 4 weeks prior to Week 0 of any of the following: * Monoamine oxidase inhibitors (MAOIs): used to treat depression and Parkinson's disease. * Medications that regulate the neurotransmitter serotonin in the brain (SSRIs): used to treat psychiatric disorders and to stop smoking. * Amino acids: used to treat sleep disorders. * Certain antimigraine drugs (such as sumatriptan, dihydroergotamine). * Opioids (such as pentazocine, pethidine, fentanyl, dextromethorphan). * Organic causes of obesity (e.g., hypothyroidism). * History of major eating disorders, such as anorexia nervosa or bulimia nervosa. * History of benign prostatic hyperplasia with urinary retention. * History of neurological disorders such as seizures. * History of documented psychiatric illnesses such as anxiety, depression, bipolar disorder or schizophrenia or having psychotic symptoms. * History or evidence of severe renal or hepatic impairments. * History of narrow-angle glaucoma. * History of coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, arrhythmia or cerebrovascular disease (transient ischemic attacks or strokes).13. History or evidence of hyperthyroidism. * Persistent tachycardia at rest, i.e., heart rate \>100 bpm (average of 3 measurements). * History of primary or secondary pulmonary hypertension. * Underlying or suspected phaeochromocytoma. * Known hypersensitivity to sibutramine hydrochloride monohydrate or any other component of the product. * Known history of drug or alcohol abuse. * Has previous history with the use of sibutramine. * Any other medical illnesses judged by the investigator that may compromise the efficacy or safety of sibutramine. * Unlikely to cooperate in the study